clinical trial · NCT07002216
BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma
University of Miami·phase2·recruiting·n = 48
Hodgkin LymphomaAdvanced Hodgkin LymphomaBrentuximab VedotinEtoposideCyclophosphamideDoxorubicinDacarbazineDexamethasone
brief summary
The purpose of this study is to further assess the efficacy and tolerability of a regimen of Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone (BrECADD) in patients with Stage 2 B-IV Hodgkin Lymphoma (HL) with an exploratory objective to assess the clinical utility of Circulating tumor DNA (ctDNA) as a biomarker for minimal residual disease (MRD) and depth of treatment response.
started
Jul 15, 2025
primary completion
Jul 15, 2030
completion
Jul 15, 2030
last updated
Nov 3, 2025
official title
A Phase 2 Trial of Abbreviated Brentuximab Vedotin, Etoposide, Cyclophosphamide, Adriamycin, Dacarbazine, and Dexamethasone (BrECADD) Therapy in Stage 2 B-IV Hodgkin Lymphoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol